BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 24196616)

  • 21. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
    Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
    World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas.
    Schoedel KE; Finkelstein SD; Ohori NP
    Diagn Cytopathol; 2006 Sep; 34(9):605-8. PubMed ID: 16900481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid.
    Sawhney MS; Devarajan S; O'Farrel P; Cury MS; Kundu R; Vollmer CM; Brown A; Chuttani R; Pleskow DK
    Gastrointest Endosc; 2009 May; 69(6):1106-10. PubMed ID: 19249035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
    Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
    Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.
    Kanda M; Matthaei H; Wu J; Hong SM; Yu J; Borges M; Hruban RH; Maitra A; Kinzler K; Vogelstein B; Goggins M
    Gastroenterology; 2012 Apr; 142(4):730-733.e9. PubMed ID: 22226782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
    Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
    Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commercial molecular panels are of limited utility in the classification of pancreatic cystic lesions.
    Panarelli NC; Sela R; Schreiner AM; Crapanzano JP; Klimstra DS; Schnoll-Sussman F; Pochapin MB; Yantiss RK
    Am J Surg Pathol; 2012 Oct; 36(10):1434-43. PubMed ID: 22982886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular pathogenesis of intraductal papillary mucinous neoplasms of the pancreas.
    Thosani N; Dasari CS; Bhutani MS; Raimondo M; Guha S
    Pancreas; 2010 Nov; 39(8):1129-33. PubMed ID: 20881900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pancreatic cancer].
    Schmid RM
    Praxis (Bern 1994); 2006 Nov; 95(44):1709-12. PubMed ID: 17111879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.